Key Points

  • NS-causing SHP2 gain-of-function mutation induces a signaling defect–related thrombopathy with an increased bleeding risk.

  • NSML-causing SHP2 loss of function induces an elevated platelet response to collagen at high shear rate.

Abstract

Src homology 2 domain–containing phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a ubiquitous protein tyrosine phosphatase that is a critical regulator of signal transduction. Germ line mutations in the PTPN11 gene responsible for catalytic gain or loss of function of SHP2 cause 2 disorders with multiple organ defects: Noonan syndrome (NS) and NS with multiple lentigines (NSML), respectively. Bleeding anomalies have been frequently reported in NS, but causes remain unclear. This study investigates platelet activation in patients with NS and NSML and in 2 mouse models carrying PTPN11 mutations responsible for these 2 syndromes. Platelets from NS mice and patients displayed a significant reduction in aggregation induced by low concentrations of GPVI and CLEC-2 agonists and a decrease in thrombus growth on a collagen surface under arterial shear stress. This was associated with deficiencies in GPVI and αIIbβ3 integrin signaling, platelet secretion, and thromboxane A2 generation. Similarly, arterial thrombus formation was significantly reduced in response to a local carotid injury in NS mice, associated with a significant increase in tail bleeding time. In contrast, NSML mouse platelets exhibited increased platelet activation after GPVI and CLEC-2 stimulation and enhanced platelet thrombotic phenotype on collagen matrix under shear stress. Blood samples from NSML patients also showed a shear stress–dependent elevation of platelet responses on collagen matrix. This study brings new insights into the understanding of SHP2 function in platelets, points to new thrombopathies linked to platelet signaling defects, and provides important information for the medical care of patients with NS in situations involving risk of bleeding.

REFERENCES

REFERENCES
1.
Tajan
M
,
Paccoud
R
,
Branka
S
,
Edouard
T
,
Yart
A
.
The RASopathy family: consequences of germline activation of the RAS/MAPK pathway
.
Endocr Rev
.
2018
;
39
(
5
):
676
-
700
.
2.
Tartaglia
M
,
Gelb
BD
,
Zenker
M
.
Noonan syndrome and clinically related disorders
.
Best Pract Res Clin Endocrinol Metab
.
2011
;
25
(
1
):
161
-
179
.
3.
Tartaglia
M
,
Zampino
G
,
Gelb
BD
.
Noonan syndrome: clinical aspects and molecular pathogenesis
.
Mol Syndromol
.
2010
;
1
(
1
):
2
-
26
.
4.
Keren
B
,
Hadchouel
A
,
Saba
S
, et al;
French Collaborative Noonan Study Group
.
PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience
.
J Med Genet
.
2004
;
41
(
11
):
e117
.
5.
Tartaglia
M
,
Mehler
EL
,
Goldberg
R
, et al
.
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome [published corrections appear in Nat Genet. 2001;29(4):491 and Nat Genet. 2002;30(1):123
.
Nat Genet
.
2001
;
29
(
4
):
465
-
468
.
6.
Tartaglia
M
,
Martinelli
S
,
Stella
L
, et al
.
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
.
Am J Hum Genet
.
2006
;
78
(
2
):
279
-
290
.
7.
Artoni
A
,
Selicorni
A
,
Passamonti
SM
, et al
.
Hemostatic abnormalities in Noonan syndrome
.
Pediatrics
.
2014
;
133
(
5
):
e1299
-
e1304
.
8.
Nugent
DJ
,
Romano
AA
,
Sabharwal
S
,
Cooper
DL
.
Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review
.
J Blood Med
.
2018
;
9
:
185
-
192
.
9.
Sharland
M
,
Patton
MA
,
Talbot
S
,
Chitolie
A
,
Bevan
DH
.
Coagulation-factor deficiencies and abnormal bleeding in Noonan’s syndrome
.
Lancet
.
1992
;
339
(
8784
):
19
-
21
.
10.
Briggs
BJ
,
Dickerman
JD
.
Bleeding disorders in Noonan syndrome
.
Pediatr Blood Cancer
.
2012
;
58
(
2
):
167
-
172
.
11.
Sharland
M
,
Burch
M
,
McKenna
WM
,
Paton
MA
.
A clinical study of Noonan syndrome
.
Arch Dis Child
.
1992
;
67
(
2
):
178
-
183
.
12.
Zenker
M
,
Buheitel
G
,
Rauch
R
, et al
.
Genotype-phenotype correlations in Noonan syndrome
.
J Pediatr
.
2004
;
144
(
3
):
368
-
374
.
13.
Bertola
DR
,
Carneiro
JD
,
D’Amico
EA
, et al
.
Hematological findings in Noonan syndrome
.
Rev Hosp Clin Fac Med Sao Paulo
.
2003
;
58
(
1
):
5
-
8
.
14.
de Haan
M
,
vd Kamp
JJ
,
Briët
E
,
Dubbeldam
J
.
Noonan syndrome: partial factor XI deficiency
.
Am J Med Genet
.
1988
;
29
(
2
):
277
-
282
.
15.
Massarano
AA
,
Wood
A
,
Tait
RC
,
Stevens
R
,
Super
M
.
Noonan syndrome: coagulation and clinical aspects
.
Acta Paediatr
.
1996
;
85
(
10
):
1181
-
1185
.
16.
Wiegand
G
,
Hofbeck
M
,
Zenker
M
,
Budde
U
,
Rauch
R
.
Bleeding diathesis in Noonan syndrome: is acquired von Willebrand syndrome the clue?
Thromb Res
.
2012
;
130
(
5
):
e251
-
e254
.
17.
Tajan
M
,
de Rocca Serra
A
,
Valet
P
,
Edouard
T
,
Yart
A
.
SHP2 sails from physiology to pathology
.
Eur J Med Genet
.
2015
;
58
(
10
):
509
-
525
.
18.
Yang
W
,
Klaman
LD
,
Chen
B
, et al
.
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival
.
Dev Cell
.
2006
;
10
(
3
):
317
-
327
.
19.
Senis
YA
.
Protein-tyrosine phosphatases: a new frontier in platelet signal transduction
.
J Thromb Haemost
.
2013
;
11
(
10
):
1800
-
1813
.
20.
Fan
X
,
Shi
P
,
Dai
J
, et al
.
Paired immunoglobulin-like receptor B regulates platelet activation
.
Blood
.
2014
;
124
(
15
):
2421
-
2430
.
21.
Mazharian
A
,
Wang
YJ
,
Mori
J
, et al
.
Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function
.
Sci Signal
.
2012
;
5
(
248
):
ra78
.
22.
Moraes
LA
,
Barrett
NE
,
Jones
CI
, et al
.
Platelet endothelial cell adhesion molecule-1 regulates collagen-stimulated platelet function by modulating the association of phosphatidylinositol 3-kinase with Grb-2-associated binding protein-1 and linker for activation of T cells
.
J Thromb Haemost
.
2010
;
8
(
11
):
2530
-
2541
.
23.
Mazharian
A
,
Mori
J
,
Wang
YJ
, et al
.
Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function
.
Blood
.
2013
;
121
(
20
):
4205
-
4220
.
24.
Hu
M
,
Liu
P
,
Liu
Y
, et al
.
Platelet Shp2 negatively regulates thrombus stability under high shear stress
.
J Thromb Haemost
.
2019
;
17
(
1
):
220
-
231
.
25.
Araki
T
,
Mohi
MG
,
Ismat
FA
, et al
.
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation
.
Nat Med
.
2004
;
10
(
8
):
849
-
857
.
26.
Sarkozy
A
,
Digilio
MC
,
Dallapiccola
B
.
Leopard syndrome
.
Orphanet J Rare Dis
.
2008
;
3
:
13
.
27.
Tajan
M
,
Batut
A
,
Cadoudal
T
, et al
.
LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity
.
Proc Natl Acad Sci USA
.
2014
;
111
(
42
):
E4494
-
E4503
.
28.
Valet
C
,
Chicanne
G
,
Severac
C
, et al
.
Essential role of class II PI3K-C2α in platelet membrane morphology
.
Blood
.
2015
;
126
(
9
):
1128
-
1137
.
29.
Auger
JM
,
Kuijpers
MJ
,
Senis
YA
,
Watson
SP
,
Heemskerk
JW
.
Adhesion of human and mouse platelets to collagen under shear: a unifying model
.
FASEB J
.
2005
;
19
(
7
):
825
-
827
.
30.
Du
X
.
Signaling and regulation of the platelet glycoprotein Ib-IX-V complex
.
Curr Opin Hematol
.
2007
;
14
(
3
):
262
-
269
.
31.
Furie
B
,
Furie
BC
.
Mechanisms of thrombus formation
.
N Engl J Med
.
2008
;
359
(
9
):
938
-
949
.
32.
Watson
SP
,
Herbert
JM
,
Pollitt
AY
.
GPVI and CLEC-2 in hemostasis and vascular integrity
.
J Thromb Haemost
.
2010
;
8
(
7
):
1456
-
1467
.
33.
Tosetto
A
,
Castaman
G
,
Rodeghiero
F
.
Assessing bleeding in von Willebrand disease with bleeding score
.
Blood Rev
.
2007
;
21
(
2
):
89
-
97
.
34.
Chen
YN
,
LaMarche
MJ
,
Chan
HM
, et al
.
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
.
Nature
.
2016
;
535
(
7610
):
148
-
152
.
35.
Zhao
H
,
Martin
E
,
Matalkah
F
, et al
.
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
.
Oncogene
.
2019
;
38
(
13
):
2275
-
2290
.
36.
Dardaei
L
,
Wang
HQ
,
Singh
M
, et al
.
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
.
Nat Med
.
2018
;
24
(
4
):
512
-
517
.
37.
Sun
X
,
Ren
Y
,
Gunawan
S
, et al
.
Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099
.
Leukemia
.
2018
;
32
(
5
):
1246
-
1249
.
38.
Geer
MJ
,
van Geffen
JP
,
Gopalasingam
P
, et al
.
Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis
.
Blood
.
2018
;
132
(
13
):
1413
-
1425
.
39.
Stewart
RA
,
Sanda
T
,
Widlund
HR
, et al
.
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis
.
Dev Cell
.
2010
;
18
(
5
):
750
-
762
.
40.
Yu
ZH
,
Xu
J
,
Walls
CD
, et al
.
Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations
.
J Biol Chem
.
2013
;
288
(
15
):
10472
-
10482
.
41.
Limongelli
G
,
Pacileo
G
,
Marino
B
, et al
.
Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome
.
Am J Cardiol
.
2007
;
100
(
4
):
736
-
741
.
You do not currently have access to this content.